Market evolution: Pyrimidine and piperazine compounds (CN 293359) — 2015–2025

Introduction

This report examines the evolution of EU trade in pyrimidine and piperazine compounds (CN 293359) over the 2015–2025 period. The product category covers a broad range of nitrogen-containing heterocyclic compounds used across pharmaceutical, agrochemical, and industrial applications, including key intermediates for drug synthesis and catalysts such as 1,4-diazabicyclo[2.2.2]octane (triethylenediamine).

The decade under review reveals a dramatic transformation in the EU's trade position. Between 2015 and 2025, the EU shifted from being a significant net exporter to a net importer, while simultaneously experiencing an extraordinary price escalation that has fundamentally altered the value composition of trade flows. These changes reflect broader structural shifts in global chemical supply chains, with profound implications for European industrial competitiveness and strategic autonomy.

For a complete overview of the data, see the General Overview dashboard.

1. From net exporter to net importer: A structural reversal in trade balance

The trade balance underwent a historic reversal

The most striking feature of EU trade in CN 293359 over the decade is the complete inversion of the trade balance. In 2015, the EU recorded a trade surplus of approximately €2.69 billion. By 2025, this had transformed into a deficit of approximately €2.04 billion — a swing of nearly €4.7 billion.

The divergence is driven not by a collapse in exports — which actually grew — but by the explosive growth of imports, whose value nearly tripled over the period.

China emerged as the dominant import source

The geographic restructuring of EU imports has been dramatic. China's share of EU imports grew from €221 million in 2015 to €3.26 billion in 2025, representing a staggering 1,371.8% increase. This made China the single largest supplier to the EU market.

Switzerland remained a major supplier (growing from €2.17 billion to €3.95 billion), but China's ascent was far more rapid. This pattern is consistent with the broader trend of Chinese chemical manufacturers scaling up production of pharmaceutical intermediates and specialty chemicals, often benefiting from integrated supply chains and cost advantages.

Meanwhile, the United Kingdom's role as an import source collapsed from €363 million to €63 million (−82.6%), likely reflecting both Brexit-related trade friction and shifts in supply chain routing.

Export markets consolidated around the United States

On the export side, the United States consolidated its position as the EU's primary export destination, growing from €2.55 billion (2015) to €3.98 billion (2025), a 55.9% increase. The US now accounts for a dominant share of EU exports.

The UK's share of EU exports fell sharply from €685 million to €96 million (−85.9%), mirroring the import-side decline and again pointing to Brexit as a structural disruptor. Notable growth also occurred in exports to Russia (from €16 million to €112 million, +587.7%) and Singapore (from €8 million to €52 million, +539.0%), though these remained relatively small in absolute terms.

For more details on partner dynamics, see the by-country partners dashboard.

2. A price-driven market: Rising unit values mask declining physical volumes

Import and export volumes declined while values surged

A defining characteristic of the 2015–2025 period is the decoupling of value and volume trends. Both import and export volumes fell, yet trade values increased substantially — driven by a sharp rise in unit prices.

Import prices nearly quadrupled over the decade, rising from approximately €180,000 per tonne to nearly €700,000 per tonne. Export prices more than doubled, from approximately €262,000 to €576,000 per tonne.

The dominant product subcategory drives price dynamics

The breakdown by subcategory reveals that the residual category 29335995 (which encompasses the broad set of pyrimidine and piperazine compounds excluding diazinon and triethylenediamine) accounts for the vast majority of trade in both volume and value terms.

Within this residual category, import prices rose from €185,852/t to €729,584/t (+292.6%), while export prices rose from €262,335/t to €577,335/t (+120.1%). The narrowing gap between export and import unit prices in 2025 (€576,000 vs. €697,000) contrasts with the 2015 situation (€262,000 vs. €180,000), suggesting a shift in the composition of traded products or in bargaining power.

For the full product segment breakdown, see the cross-section comparison dashboard.

Domestic production expanded significantly

EU production data (sourced from PRODCOM) shows a substantial expansion in domestic output over the period. Production quantity grew from 15,000 tonnes (2015) to 34,800 tonnes (2025), a 132% increase. Production value grew even more dramatically, from €765 million to €6.34 billion (+728.4%).

The fact that production value grew far more rapidly than quantity (a 728% increase in value versus 132% in quantity) confirms that the price escalation observed in trade data is also reflected in domestic production. This suggests that the price increases are not merely a trade phenomenon but reflect genuine shifts in the cost structure or product mix of the industry.

For production volume trends, see the production volumes dashboard.

3. Market concentration, specialization, and vulnerability indicators

Export concentration increased markedly

The Herfindahl-Hirschman Index (HHI) for EU exports by partner country rose from 3,449 to 5,054 (+46.5%) over the period, indicating growing concentration of exports toward a smaller number of destinations. The dominant role of the United States as an export market is the primary driver of this trend.

Import concentration remained relatively stable (HHI rising modestly from 3,853 to 4,128), as growth from China and Switzerland partially offset declines from other sources.

For concentration data, see the concentration dashboard.

Ireland is the EU's dominant exporter; Germany leads on imports

Among EU Member States, Ireland emerged as the overwhelmingly dominant exporter of CN 293359 products. In 2025, Ireland accounted for €3.95 billion in exports — nearly 44% of total EU exports. Ireland also shows the highest revealed comparative advantage (RCA of 14.30) and a strong normalized RCA (RSCA of 0.87), confirming deep specialization.

On the import side, Germany remained the largest importer (€2.01 billion), followed by Slovenia (€1.20 billion, a remarkable increase from just €7 million in 2015) and Ireland (€434 million, +103.0%).

The extraordinary growth of Slovenia as an import hub (from €7 million to over €1.2 billion) may reflect the establishment or expansion of pharmaceutical manufacturing or warehousing operations in the country, potentially by multinational firms optimizing their European supply chains.

For data on Member State specialization, see the specialisation dashboard.

Supply-side volatility and detected shocks

Price volatility varied significantly across trading partners. For EU imports, the United Kingdom showed the highest coefficient of variation (CV = 1.12), followed by Switzerland (0.34) and China (0.15). The relatively low CV for China despite its rapid growth suggests a steady, scaling-up pattern rather than erratic swings.

The most significant detected shock events include:

The UK import price shock in 2019 (a 741% price increase with an abnormality score of 11.2) is particularly striking and likely reflects a combination of supply disruptions, trade reclassification effects, or compositional shifts in the product mix around the time of Brexit.

For volatility and shock data, see the supply shocks dashboard.

Net import reliance shifted decisively

The EU's net import reliance shifted from −47.5% in 2015 (indicating net exporter status) to +31.9% in 2025 (indicating net importer status). This swing of over 167 percentage points underscores the structural transformation of the EU's position in this market.

Export propensity (the ratio of exports to domestic production) declined from 133.2% to 115.5%, while trade intensity (the sum of imports and exports relative to production plus imports) fell from 116.5% to 105.9%. Both metrics suggest a market that is becoming somewhat more domestically oriented in production terms, even as import dependency rises.

Conclusion

The EU market for pyrimidine and piperazine compounds (CN 293359) underwent a fundamental transformation between 2015 and 2025. Three defining dynamics emerge from the data:

1. Trade balance reversal: The EU shifted from a position of net exporter (with a €2.7 billion surplus in 2015) to net importer (with a €2.0 billion deficit in 2025). This was driven primarily by the explosive growth of imports from China (+1,372%) and sustained supply from Switzerland.

2. Price-driven value growth: Physical trade volumes declined for both imports (−25.5%) and exports (−37.6%), yet trade values surged due to a dramatic escalation in unit prices. Import prices nearly quadrupled (from €180,000/t to €697,000/t), reflecting shifts in product mix, input costs, and potentially increased demand for high-value pharmaceutical intermediates.

3. Geographic concentration and vulnerability: Export markets became more concentrated around the United States, while import sources consolidated around China and Switzerland. The UK's role diminished sharply on both sides of the trade balance, likely as a consequence of Brexit. The growing dependence on Chinese supply, combined with rising prices and concentration, introduces potential strategic vulnerabilities for the EU pharmaceutical and chemical industries.

These trends call for continued monitoring of supply chain resilience, particularly as geopolitical tensions and trade policy shifts may further reshape the competitive landscape for this strategically important product category.